Kiora Pharmaceuticals Analyst Ratings
Kiora Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/24/2023 | 220% | HC Wainwright & Co. | → $2 | Reiterates | Buy → Buy |
| 08/14/2023 | 220% | HC Wainwright & Co. | $7 → $2 | Maintains | Buy |
| 08/09/2023 | 220% | Maxim Group | $12 → $2 | Maintains | Buy |
| 05/12/2023 | 1020% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 03/24/2023 | 860% | HC Wainwright & Co. | $10 → $6 | Reiterates | → Buy |
| 02/09/2023 | 1820% | Maxim Group | → $12 | Upgrades | Hold → Buy |
| 02/08/2023 | 1500% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 02/08/2023 | 18940% | Ladenburg Thalmann | → $119 | Reiterates | → Buy |
| 08/25/2022 | 940% | Ladenburg Thalmann | → $6.5 | Initiates Coverage On | → Buy |
| 08/15/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/11/2022 | 300% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 04/19/2022 | 380% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 01/19/2022 | 300% | Maxim Group | → $2.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/24/2023 | 220% | HC Wainwright & Co. | → 2 美元 | 重申 | 购买 → 购买 |
| 08/14/2023 | 220% | HC Wainwright & Co. | 7 美元 → 2 美元 | 维护 | 购买 |
| 08/09/2023 | 220% | Maxim 集团 | 12 美元 → 2 美元 | 维护 | 购买 |
| 05/12/2023 | 1020% | HC Wainwright & Co. | 6 美元 → 7 美元 | 维护 | 购买 |
| 2023 年 3 月 24 日 | 860% | HC Wainwright & Co. | 10 美元 → 6 美元 | 重申 | → 购买 |
| 02/09/2023 | 1820% | Maxim 集团 | → 12 美元 | 升级 | 持有 → 买入 |
| 02/08/2023 | 1500% | HC Wainwright & Co. | → 10 美元 | 重申 | → 购买 |
| 02/08/2023 | 18940% | 拉登堡塔尔曼 | → 119 美元 | 重申 | → 购买 |
| 08/25/2022 | 940% | 拉登堡塔尔曼 | → 6.5 美元 | 启动覆盖开启 | → 购买 |
| 08/15/2022 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 2022 年 11 月 7 日 | 300% | HC Wainwright & Co. | $3 → 2.5 美元 | 维护 | 购买 |
| 04/19/2022 | 380% | HC Wainwright & Co. | 5 美元 → 3 美元 | 维护 | 购买 |
| 2022 年 1 月 19 日 | 300% | Maxim 集团 | → 2.5 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的目标价格是多少？
The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $2.00 expecting KPRX to rise to within 12 months (a possible 220.00% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月24日公布了Kiora Pharmicals（纳斯达克股票代码：KPRX）的最新目标股价。该分析公司将目标股价定为2.00美元，预计KPRX将在12个月内升至220.00％（可能上涨220.00％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的最新分析师评级是多少？
The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.
Kiora Pharmicals（纳斯达克股票代码：KPRX）的最新分析师评级由HC Wainwright & Co. 提供，Kiora Pharmicals重申了买入评级。
When is the next analyst rating going to be posted or updated for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与Kiora Pharmicals的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Kiora Pharmicals的最后一次评级是在2023年8月24日提交的，因此你应该预计下一个评级将在2024年8月24日左右公布。
Is the Analyst Rating Kiora Pharmaceuticals (KPRX) correct?
分析师对Kiora Pharmicals（KPRX）的评级正确吗？
While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $2.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.63, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但重申了最新的Kiora Pharmicals（KPRX）评级，目标股价为0.00美元至2.00美元。Kiora Pharmicals（KPRX）目前的交易价格为0.63美元，在分析师的预测区间内。